| Trial ID: | L1083 |
| Source ID: | NCT00648167
|
| Associated Drug: |
Ferric Citrate
|
| Title: |
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00648167/results
|
| Conditions: |
Hyperphosphatemia|End-stage Renal Disease
|
| Interventions: |
DRUG: ferric citrate
|
| Outcome Measures: |
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28), 28 days |
|
| Sponsor/Collaborators: |
Sponsor: Keryx Biopharmaceuticals | Collaborators: Collaborative Study Group (CSG)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
55
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-03
|
| Completion Date: |
2009-01
|
| Results First Posted: |
2014-10-09
|
| Last Update Posted: |
2017-04-04
|
| Locations: |
Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00648167
|
